Study of GDF15's impact on energy balance and inflammation has led to clinical development of GDF15‐mimetics for obesity and metabolic syndrome and GDF15‐inhibitors or antagonists for cancer‐related cachexia, immunosuppression and heart disease [11]. This evidence concerns the gene GDF15 and metabolic syndrome.